Hepatitis A Vaccine
- Generic Name
- Hepatitis A Vaccine
- Brand Names
- Avaxim, Havrix, Twinrix, Vaqta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection a...
- Indication
Hepatitis A vaccine is indicated for immunization against hepatitis A virus (HAV) infection in patients aged 12 months and older, and the first dose should be administered at least 2 weeks before expected exposure to the Hepatitis A virus.
- Associated Conditions
- Hepatitis A, Disease caused by Salmonella typhi
- Associated Therapies
- -
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- Conditions
- Interventions
- Biological: Investigational varicella vaccine_Lot 1Biological: Investigational varicella vaccine_Lot 2Biological: Investigational varicella vaccine_Lot 3Biological: Marketed varicella vaccine_Lot 1Biological: Marketed varicella vaccine_Lot 2Biological: MMR vaccineBiological: Hepatitis A vaccineBiological: PCV (pneumococcal conjugate vaccine) 13Biological: PCV 20Biological: Vaxneuvance
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1840
- Registration Number
- NCT06740630
- Locations
- 🇦🇪
GSK Investigational Site, Abu Dhabi, United Arab Emirates
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 750
- Registration Number
- NCT06693895
- Locations
- 🇵🇱
GSK Investigational Site, Warszawa, Poland
Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa
- Conditions
- Interventions
- Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate VaccineBiological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate VaccineBiological: Pneumoccocal VaccineBiological: Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)Biological: Measles, Mumps, and Rubella Vaccine live (MMR)Biological: DTwP-HepB-Hib-IPV vaccineBiological: DTaP-IPV-Hib-HepB vaccineBiological: Hepatitis A vaccineBiological: Rotavirus vaccineBiological: Measles vaccineBiological: Typhoid conjugate vaccine (TCV)Biological: Varicella vaccine live
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1528
- Registration Number
- NCT05794230
- Locations
- 🇮🇳
Investigational Site Number : 3560006, Chennai, India
🇮🇳Investigational Site Number : 3560007, Hyderabad, India
🇮🇳Investigational Site Number : 3560016, Kanpur, India
Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali
- Conditions
- Interventions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2024-10-22
- Target Recruit Count
- 1301
- Registration Number
- NCT03917654
- Locations
- 🇲🇱
Mrtc/Usttb, Bamako, Mali
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
- Conditions
- Interventions
- Biological: MenACYW conjugate vaccineBiological: MenACYW-135 conjugate vaccineBiological: DTaP-IPV//Hib vaccineBiological: Pneumococcal 13-valent conjugate vaccineBiological: Pentavalent rotavirus vaccineBiological: Hepatitis B vaccineBiological: Measles, mumps, rubella (MMR) vaccineBiological: Varicella vaccineBiological: Hepatitis A vaccine
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 2627
- Registration Number
- NCT03537508
- Locations
- 🇺🇸
Helios Clinical Research Site Number : 8400109, Houston, Texas, United States
🇺🇸Wee Care Pediatrics Syracuse Site Number : 8400024, Syracuse, Utah, United States
🇺🇸Birmingham Pediatric Associates Site Number : 8400026, Birmingham, Alabama, United States
Effects of Aging on Primary and Secondary Vaccine Responses
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 54
- Registration Number
- NCT03312699
- Locations
- 🇺🇸
Stanford LPCH Vaccine Program, Stanford, California, United States
PCV13 + Hepatitis a Vaccine for Adults
- Conditions
- Interventions
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 305
- Registration Number
- NCT01926860
- Locations
- 🇫🇮
Aava Medical Centre, Helsinki, Finland
🇸🇪Department of Infectious Diseases, Eskilstuna, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.